NCCN Guidelines® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines
Al B. Benson,Alan P. Venook,Mahmoud M. Al-Hawary,Lynette Cederquist,Yi Jen Chen,Kristen K. Ciombor,Stacey Cohen,Harry S. Cooper,Dustin A. Deming,Paul F. Engstrom,Ignacio Garrido-Laguna,Jean L. Grem,Axel Grothey,Howard S. Hochster,Sarah E. Hoffe,Steven C. Hunt,Ahmed Kamel,Natalie Kirilcuk,Smitha S. Krishnamurthi,Wells A. Messersmith,Jeffrey A. Meyerhardt,Eric D. Miller,Mary F. Mulcahy,James D. Murphy,Steven J. Nurkin,Leonard B. Saltz,Sunil Sharma,David Shibata,John M. Skibber,Constantinos T. Sofocleous,Elena M. Stoffel,Eden Stotsky-Himelfarb,Christopher G. Willett,Evan Wuthrick,Kristina M. Gregory,Deborah A. Freedman-Cass +35 more
TLDR
The NCCN Colon Cancer Panel discussions for the 2018 update of the guidelines regarding risk stratification and adjuvant treatment for patients with stage III colon cancer, and treatment of BRAF V600E mutation-positive metastatic colorectal cancer with regimens containing vemurafenib are summarized.Abstract:
The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, and survivorship. These NCCN Guidelines Insights summarize the NCCN Colon Cancer Panel discussions for the 2018 update of the guidelines regarding risk stratification and adjuvant treatment for patients with stage III colon cancer, and treatment of BRAF V600E mutation-positive metastatic colorectal cancer with regimens containing vemurafenib.read more
Citations
More filters
Journal ArticleDOI
Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2020
Cesare Hassan,Giulio Antonelli,Jean-Marc Dumonceau,Jaroslaw Regula,Michael Bretthauer,Stanislas Chaussade,Evelien Dekker,Monika Ferlitsch,Antonio Z. Gimeno-García,Rodrigo Jover,Mette Kalager,Maria Pellise,Christian Pox,Luigi Ricciardiello,Matthew D. Rutter,Lise Mørkved Helsingen,Arne Bleijenberg,Carlo Senore,Jeanin E. van Hooft,Mário Dinis-Ribeiro,Enrique Quintero +20 more
TL;DR: The following recommendations for post-polypectomy colonoscopic surveillance apply to all patients who had one or more polyps that were completely removed during a high quality baseline colonoscopy.
Journal ArticleDOI
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.
Josep Tabernero,Axel Grothey,Eric Van Cutsem,Rona Yaeger,Harpreet Wasan,Takayuki Yoshino,Jayesh Desai,Fortunato Ciardiello,Fotios Loupakis,Yong Sang Hong,Neeltje Steeghs,Tormod Kyrre Guren,Hendrik Tobias Arkenau,Pilar García-Alfonso,Elena Elez,Ashwin Gollerkeri,K. Maharry,Janna Christy-Bittel,Scott Kopetz +18 more
TL;DR: PURPOSEBEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators' choice of irinotecan or FOLFIRI plus CetuxIMB in patients with BRAFV600E-mutant metastatic...
Journal ArticleDOI
Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline.
E. Gabriela Chiorean,Govind Nandakumar,Temidayo Fadelu,Sarah Temin,Ashley Efrain Alarcon-Rozas,Suyapa Bejarano,Adina-Emilia Croitoru,Surbhi Grover,Pritesh V. Lohar,Andrew Odhiambo,Se Hoon Park,Erika Ruiz Garcia,Catherine Teh,Azmina Rose,Bassem I. Zaki,Mary D. Chamberlin +15 more
TL;DR: The resource-stratified, evidence-based recommendations on the treatment and follow-up of patients with early-stage colorectal cancer are provided to complement but not replace local guidelines.
Journal ArticleDOI
The Prognostic Implications of Tumor Infiltrating Lymphocytes in Colorectal Cancer: A Systematic Review and Meta-Analysis.
TL;DR: The results demonstrate that high levels of generalized TILS as compared to low levels had an improved overall survival (OS) and suggest that TILs and specific TIL subsets serve as prognostic biomarkers for colorectal cancer.
Journal ArticleDOI
Lynch Syndrome-Associated Colorectal Cancer.
TL;DR: Evidence supporting various strategies is presented, followed by a review of formal guidelines, when they exist, and the article ends with the author's clinical recommendations.
References
More filters
Journal ArticleDOI
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Soonmyung Paik,Steven Shak,Gong Tang,Chungyeul Kim,Joffre B. Baker,Maureen T. Cronin,Frederick L. Baehner,Michael G. Walker,Drew Watson,Taesung Park,William Hiller,Edwin R. Fisher,D. Lawrence Wickerham,John Bryant,Norman Wolmark +14 more
TL;DR: The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor-positive breast cancer and could be used as a continuous function to predict distant recurrent in individual patients.
Journal ArticleDOI
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
Soonmyung Paik,Gong Tang,Steven Shak,Chungyeul Kim,Joffre B. Baker,Wanseop Kim,Maureen T. Cronin,Frederick L. Baehner,Drew Watson,John Bryant,Joseph P. Costantino,Charles E. Geyer,D. Lawrence Wickerham,Norman Wolmark +13 more
TL;DR: The RS assay not only quantifies the likelihood of breast cancer recurrence in women with node-negative, estrogen receptor-positive breast cancer, but also predicts the magnitude of chemotherapy benefit.
Journal ArticleDOI
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano,Robert Gray,Della F. Makower,Kathleen I. Pritchard,Kathy S. Albain,Daniel F. Hayes,Daniel F. Hayes,Charles E. Geyer,Elizabeth Claire Dees,Matthew P. Goetz,John A. Olson,John A. Olson,Tracy Lively,Sunil Badve,Thomas J. Saphner,Lynne I. Wagner,Timothy J. Whelan,Matthew J. Ellis,Soonmyung Paik,William C. Wood,Peter M. Ravdin,Maccon M. Keane,Henry L. Gomez Moreno,Pavan S. Reddy,Timothy F. Goggins,Ingrid A. Mayer,Adam Brufsky,Deborah Toppmeyer,Virginia G. Kaklamani,Jeffery L. Berenberg,Jeffrey Abrams,George W. Sledge +31 more
TL;DR: In this paper, the authors performed a prospective trial involving 10,273 women with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer.
Journal ArticleDOI
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Fatima Cardoso,Laura J. van't Veer,Jan Bogaerts,Leen Slaets,Giuseppe Viale,Suzette Delaloge,Jean-Yves Pierga,Etienne Brain,Sylvain Causeret,Mauro Delorenzi,Annuska M. Glas,Vassilis Golfinopoulos,Theodora Goulioti,Susan J. Knox,Erika Matos,Bart Meulemans,Peter A. Neijenhuis,Ulrike Nitz,Rodolfo Passalacqua,Peter M. Ravdin,Isabel T. Rubio,Mahasti Saghatchian,Tineke J. Smilde,Christos Sotiriou,Lisette Stork,Carolyn Straehle,Geraldine A. Thomas,Alastair M. Thompson,Jacobus J.M. van der Hoeven,Peter Vuylsteke,René Bernards,Konstantinos Tryfonidis,Emiel J. Th. Rutgers,Martine Piccart +33 more
TL;DR: Among women with early-stage breast cancer who were at high clinical risk and low genomic risk for recurrence, the receipt of no chemotherapy on the basis of the 70-gene signature led to a 5-year rate of survival without distant metastasis that was 1.5 percentage points lower than the rate with chemotherapy.
Journal ArticleDOI
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain,William E. Barlow,Steven Shak,Gabriel N. Hortobagyi,Robert B. Livingston,I-Tien Yeh,Peter M. Ravdin,Roberto Bugarini,Frederick L. Baehner,Nancy E. Davidson,George W. Sledge,Eric P. Winer,Clifford A. Hudis,James N. Ingle,Edith A. Perez,Kathleen I. Pritchard,Lois E. Shepherd,Julie Gralow,Carl Yoshizawa,D. Craig Allred,C. Kent Osborne,Daniel F. Hayes +21 more
TL;DR: The recurrence score is prognostic for tamoxifen-treated patients with positive nodes and predicts significant benefit of CAF in tumours with a high recurrence scores, as well as overall survival and breast-cancer-specific survival.
Related Papers (5)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem,Andrés Cervantes,René Adam,Alberto Sobrero,J.H.J.M. van Krieken,Dan Aderka,E. Aranda Aguilar,Alberto Bardelli,Al B. Benson,György Bodoky,Fortunato Ciardiello,André D'Hoore,Eduardo Díaz-Rubio,J.-Y. Douillard,Michel Ducreux,Alfredo Falcone,Axel Grothey,Thomas Gruenberger,Karin Haustermans,Volker Heinemann,Paulo M. Hoff,C.-H. Köhne,R. Labianca,Pierre Laurent-Puig,Brigette B.Y. Ma,Tim Maughan,Kei Muro,Nicola Normanno,Pia Österlund,Pia Österlund,Wim J.G. Oyen,Demetris Papamichael,George Pentheroudakis,Per Pfeiffer,Timothy J. Price,C.J.A. Punt,Jens Ricke,Arnaud Roth,R. Salazar,Werner Scheithauer,H.-J. Schmoll,Josep Tabernero,Julien Taieb,Sabine Tejpar,Harpreet Wasan,Takayuki Yoshino,Aziz Zaanan,Dirk Arnold +47 more
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Brandon Luber,Nilofer S. Azad,Daniel A. Laheru,Barbara A. Biedrzycki,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Steven M. Duffy,Richard M. Goldberg,Richard M. Goldberg,Albert de la Chapelle,Albert de la Chapelle,Minori Koshiji,Feriyl Bhaijee,Thomas Huebner,Ralph H. Hruban,Laura D. Wood,Nathan Cuka,Drew M. Pardoll,Nickolas Papadopoulos,Kenneth W. Kinzler,Shibin Zhou,Toby C. Cornish,Janis M. Taube,Robert A. Anders,James R. Eshleman,Bert Vogelstein,Luis A. Diaz +36 more